Navigation Links
Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results

CALGARY, May 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three-month period ended March 31, 2009.

"The first quarter of 2009 was highlighted by the announcement of very positive results in several of our combination REOLYSIN(R) clinical trials," said Dr. Brad Thompson, President and CEO of Oncolytics. "We continue to report clinical benefit in the majority of patients treated with REOLYSIN in combination with chemotherapy or radiation, paving the way for our pivotal program to begin this year."

    Selected First Quarter Highlights:

    -  Announced positive interim results from a U.K. Phase I/II combination
       REOLYSIN and paclitaxel/carboplatin trial for patients with advanced
       head and neck cancers. Of 12 evaluable patients, five patients had
       partial responses (PR) and four patients had stable disease (SD), for
       a clinical benefit rate (complete response + partial response + stable
       disease) of 75%;

    -  Announced positive results from a U.K. combination REOLYSIN and
       docetaxel trial for patients with a variety of advanced cancers.
       Fifteen of the 17 evaluable patients experienced SD or better,
       including two PR, three minor responses and 10 SD, giving a clinical
       benefit rate of 88%;

    -  Completed enrolment in a U.K. combination REOLYSIN and gemcitabine
       clinical trial. Of the ten patients evaluable for response, two
       patients (breast and nasopharyngeal) had PRs and five patients had SD,
       for a clinical benefit rate of 70%;

    -  Started patient enrolment in a U.S. Phase 2 Combination REOLYSIN and
       paclitaxel/carboplatin clinical trial for patients with non-small cell
       lung cancer with K-RAS or EGFR-activated tumours. Eligible patients
       include those who have not received chemotherapy treatment for their
       metastatic or recurrent disease;

    -  Started patient enrolment in a U.K. translational clinical trial
       investigating REOLYSIN in patients with metastatic colorectal cancer;

    -  Announced a multi-trial clinical research collaboration with the
       Cancer Therapy & Research Center at the University of Texas Health
       Science Center involving up to five, open-label, Phase 2 studies
       exploring the use of REOLYSIN(R) in combination with chemotherapy for
       various cancer indications. These indications are expected to include
       melanoma, pancreatic cancer, squamous cell lung, liver and K-RAS
       mutated colorectal cancers in combination with standard

    Latest Highlights

    Subsequent to quarter end, the Company announced:

    -  Positive results of a U.K. Phase II REOLYSIN and radiation combination
       clinical trial. Of 14 evaluable patients, 13 patients had SD or better
       in the treated target lesions, including four PRs and two minor
       responses, for a clinical benefit rate of 93% in the treated lesions;

    -  The successful acquisition of PrivateCo., an inactive private company
       with net cash of $2.1 million; and

    -  A proposed public offering consisting of up to 3.45 million units at
       $2.00 per unit, for gross proceeds of up to $6.9 million.

                           Oncolytics Biotech Inc.


    As at,
                                                    March 31,    December 31,
                                                      2009          2008
                                                        $             $
    Cash and cash equivalents                        7,366,481     7,429,895
    Short-term investments                           1,925,600     5,846,634
    Accounts receivable                                 68,411        86,322
    Prepaid expenses                                   101,025       179,668
                                                     9,461,517    13,542,519

    Property and equipment                             249,971       263,926

    Intellectual property                               90,375       180,750

                                                     9,801,863    13,987,195

    Accounts payable and accrued liabilities         4,273,538     4,534,111

    Shareholders' equity
    Share capital
      Authorized: unlimited number of common shares
      Issued: 43,855,748 (December 31, 2008 -
       43,830,748)                                  95,256,174    95,234,924
    Warrants                                         3,425,110     3,425,110
    Contributed surplus                             13,361,438    13,349,801
    Deficit                                       (106,514,397) (102,556,751)
                                                     5,528,325     9,453,084

                                                     9,801,863    13,987,195

                           Oncolytics Biotech Inc.

                             COMPREHENSIVE LOSS

                                     Three Month   Three Month   Cumulative
                                       Period        Period    from inception
                                       Ending        Ending       on April 2,
                                      March 31,     March 31,   1998 to March
                                        2009          2008         31, 2009
    	                                      $             $             $

    Rights revenue                             -             -       310,000
    Research and development           2,812,655     2,393,397    77,344,432
    Operating                            986,764     1,050,894    25,823,789
    Stock-based compensation              11,637        19,593     4,780,481
    Foreign exchange loss                 56,035         9,262       645,462
    Amortization - intellectual
     property                             90,375        90,375     3,524,625
    Amortization - property and
     equipment                            17,304        11,186       514,455
                                       3,974,770     3,574,707   112,633,244

    Loss before the following          3,974,770     3,574,707   112,323,244

    Interest income                      (17,124)     (180,334)   (6,551,129)

    Gain on sale of BCY LifeSciences Inc.      -             -      (299,403)

    Loss on sale of Transition
     Therapeutics Inc.                         -             -     2,156,685

    Loss before income taxes           3,957,646     3,394,373   107,629,397

    Future income tax recovery                 -             -    (1,115,000)
    Net loss and comprehensive loss
     for the period                    3,957,646     3,394,373   106,514,397

    Basic and diluted loss per share       (0.09)        (0.08)

    Weighted average number of shares
     (basic and diluted)              43,849,637    41,180,748

                           Oncolytics Biotech Inc.


                                     Three Month  Three Month       from
                                       Period        Period     inception on
                                       Ending        Ending     April 2, 1998
                                      March 31,     March 31,    to March 31,
                                        2009          2008          2009
                                          $             $             $
    Net loss for the period           (3,957,646)   (3,394,373) (106,514,397)
    Add / (deduct) non-cash items
      Amortization - intellectual
       property                           90,375        90,375     3,524,625
      Amortization - property and
       equipment                          17,304        11,186       514,455
      Stock-based compensation            11,637        19,593     4,780,481
      Other non-cash items                     -             -     1,383,537
    Net change in non-cash working
     capital                            (164,019)       24,681     4,104,102
    Cash used in operating activities (4,002,349)   (3,248,538)  (92,207,197)

    Purchase of property and equipment    (3,349)       (2,665)     (817,093)
    Purchase of short-term investments    (8,966)     (137,187)  (49,425,830)
    Redemption of short-term
     investments                       3,930,000     4,000,000    47,081,746
    Investment in BCY LifeSciences Inc.        -             -       464,602
    Investment in Transition
     Therapeutics Inc.                         -             -     2,532,343
    Cash provided by (used in)
     investing activities              3,917,685     3,860,148      (164,232)
    Proceeds from exercise of warrants
     and stock options                    21,250             -    15,322,318
    Proceeds from private placements           -             -    38,137,385
    Proceeds from public offerings                           -    46,278,207
    Cash provided by financing
     activities                           21,250             -    99,737,910
    Net increase (decrease) in cash
     and cash equivalents during the
     period                              (63,414)      611,610     7,366,481
    Cash and cash equivalents,
     beginning of the period           7,429,895     6,715,096             -
    Cash and cash equivalents, end of
     the period                        7,366,481     7,326,706     7,366,481

To view the 2009 First Quarter Report which includes the Consolidated Financial Statements, related Notes to Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's first quarter filings which will be available on and on

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics please visit

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN as a cancer therapeutic; the Company's expectations as to the success of its research and development programs in 2009 and beyond, the Company's planned operations, the value of the additional patents and intellectual property; the Company's expectations related to the applications of the patented technology; the Company's expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Details of 2009 Annual Shareholder Meeting
2. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009
3. Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
4. Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
5. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
6. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
7. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
8. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
9. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
10. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
11. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
Post Your Comments:
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader ... five states to develop and pitch their BIG ideas to improve health and wellness ... competing for votes to win the title of SAP's Teen Innovator, an all-expenses paid ...
(Date:11/24/2015)... , November 24, 2015 SHPG ) ... participate in the Piper Jaffray 27 th Annual Healthcare Conference ... December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... Chief Financial Officer, will participate in the Piper Jaffray 27 th ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. EST ...
(Date:11/24/2015)... , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today ... December 29, 2015 at 11:00 a.m. Israel time, ... Tower, 98 Yigal Allon Street, 36 th Floor, Tel ... Eric Paneth and Izhak Tamir to the Board ... Skaliter as external directors; , approval of an amendment to certain ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 Daon, a global leader in mobile ... a new version of its IdentityX Platform , ... America have already installed IdentityX v4.0 and ... FIDO UAF certified server component as an ... FIDO features. These customers include some of the largest ...
(Date:10/27/2015)... 2015 In the present market scenario, security ... various industry verticals such as banking, healthcare, defense, electronic ... demand for secure & simplified access control and growing ... hacking of bank accounts, misuse of users, , and ... PC,s, laptops, and smartphones are expected to provide potential ...
(Date:10/26/2015)... 2015  Delta ID Inc., a company focused on ... PC devices, announced its ActiveIRIS® technology powers the iris ... launched by NTT DOCOMO, INC in Japan ... smartphone to include iris recognition technology, after a very ... in May 2015, world,s first smartphone to have this ...
Breaking Biology News(10 mins):